Voting Common Stock, par value $0.0001 per share
- Symbol
- JSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 9.01 · 8-K/A
Jasper Therapeutics, Inc.
JSPRNASDAQEQUITYCurrent
Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The audited financial statements and accompanying notes of Kira Pharmaceuticals as of and for the fiscal years ended December 31, 2025 and 2024 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference.…
Company context
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
Current securities
Registered securities in this filing
JASPER THERAPEUTICS, INC. · 8-K/A · Filed 2026-10-01
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01
Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
The audited financial statements and accompanying notes of Kira Pharmaceuticals
as of and for the fiscal years ended December 31, 2025 and 2024 are filed as Exhibit 99.1 to this Current Report on Form
8-K/A and incorporated herein by reference.
The unaudited financial statements and accompanying notes of Kira Pharmaceuticals
as of and for the six months ended June 30, 2026 and 2025 are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated
herein by reference.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined balance sheet as of June
30, 2026, the unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2026, the unaudited pro
forma condensed combined statement of operations for the year ended December 31, 2025, and the related notes of Jasper Therapeutics, Inc.
with respect to the Merger, the concurrent private placement of non-voting convertible preferred stock (the “Financing”),
the distribution of contingent value rights and the Mirador License Agreement (as defined in Exhibit 99.3), are filed as Exhibit 99.3
to this Current Report on Form 8-K/A and incorporated herein by reference.
(d) Exhibits.
Exhibit No. Description
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
23.1 Consent of EisnerAmper LLP, independent auditors of Kira Pharmaceuticals.
99.1 Audited financial statements of Kira Pharmaceuticals as of December 31, 2025 and 2024 and for the years then ended.
99.2 Unaudited financial statements of Kira Pharmaceuticals
as of June 30, 2026 and for the six months ended June 30, 2026 and 2025.
99.3 Unaudited pro forma condensed combined financial information of Jasper Therapeutics, Inc. as of June 30, 2026, for the six months ended June 30, 2026, and for the year ended December 31, 2025.
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Filed exhibits (2)
Exhibit 99.1 KIRA PHARMACEUTICALS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Independent Auditors’ Report F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-6 Consolidated Statements of Cash Flows F-7 Notes to Consolidated Financial Statements F-8 F-1 INDEPENDENT AUDITORS’ REPORT To the Board of Directors and Shareholders of Kira Pharmaceuticals Report on the Audit of the Financial Statements Opinion We have audited the financial statements of Kira Pharmaceuticals (the “Company”), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders’ deficit, and cash flows for each of t…
Open exhibit ↗Exhibit 99.2 KIRA PHARMACEUTICALS INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss F-3 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-4 Condensed Consolidated Statements of Cash Flows F-5 Notes to the Condensed Consolidated Financial Statements F-6 F-1 KIRA PHARMACEUTICALS CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) June 30, December 31, 2026 2025 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────── (unaudited) Assets Current assets: Cash and cash equivalents $ …
Open exhibit ↗